Here is the complete overview of Lamivudine (A) + Nevirapine (B) + Stavudine (C) Dispersible Tablet with icons:
💊 Lamivudine + Nevirapine + Stavudine Dispersible Tablet
Each tablet contains:
- Lamivudine (A): 30 mg
- Nevirapine (B): 50 mg
- Stavudine (C): 6 mg
🧪 Nature / Drug Class
🔹 Antiretroviral combination therapy
🔹 Drug classes:
- Lamivudine – NRTI (Nucleoside Reverse Transcriptase Inhibitor)
- Stavudine – NRTI
- Nevirapine – NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor)
🔹 Triple-drug fixed-dose combination for HIV
🩺 Purpose / Indications
✅ Used for:
- 👶 Pediatric HIV-1 infection
- 👨👩👧👦 As part of first-line ART in children
- 🦠 Suppression of HIV viral load and prevention of disease progression
⚙️ Advantages
✔️ Dispersible – easy to administer to children
✔️ Fixed-dose combination improves adherence
✔️ Provides potent suppression of HIV when used consistently
✔️ Reduces pill burden, especially in resource-limited settings
📦 Common Packaging
📦 Dispersible tablets in strip or bottle packs
💧 Disperse in clean water before giving orally
🧒 Doses adjusted based on child’s weight band
⚠️ Patient Advice / Precautions
📏 Use weight-band dosing strictly (as per national HIV guidelines)
🩺 Monitor:
- Liver function (Nevirapine can cause hepatotoxicity)
- Peripheral neuropathy (Stavudine side effect)
- Hematological parameters (Lamivudine may cause anemia/neutropenia)
📛 Watch for skin rashes and signs of hypersensitivity
🕒 Give on consistent schedule for viral suppression
🚫 Contraindications / Cautions
❌ Known hypersensitivity to any of the components
⚠️ Use caution in:
- Liver disease or elevated liver enzymes
- Peripheral neuropathy or pancreatitis risk
- Co-infection with Hepatitis B (Lamivudine may cause flare-ups if withdrawn)
🧊 Storage
🌡️ Store below 25°C, in a dry place
🔒 Keep tightly closed and out of reach of children